The conversation discusses alternatives to Dr. B's hair loss treatments, specifically mentioning Minoxidil, Finasteride, and RU58841. A user notes a price discrepancy on a website.
PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.
The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.
RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.
The conversation is about hair transplants in America, specifically the availability of DHI. The user is currently using finasteride and plans to use microneedling, oral castor oil, and eventually undergo FUE or DHI.
A user is seeking recommendations for a minoxidil and tretinoin topical solution, including dosage and purchase locations in the US. They are looking for effective hair loss treatments.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
The conversation discusses the effectiveness of various supplements for hair loss, with some users suggesting higher doses of Zinc and Vitamin C, while others recommend additional supplements like Saw Palmetto and Omega-3. It is concluded that multi-vitamins are often ineffective unless there is a deficiency, and excessive intake can harm hair follicles.
Ashley & Martin Australia offers a treatment with Finasteride, Minoxidil, Retinoic Acid, a red light device, and shampoos for hair regrowth. Some users are skeptical, suggesting avoiding big companies and consulting a doctor for affordable prescriptions.
Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.
Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.
Kintor KX-826, a hair loss treatment, is being discussed for its pricing and effectiveness, with a focus on whether the 0.9% concentration is more effective than the 0.5%. Users are seeking cheaper purchasing options.
Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.
A user is experiencing worsening hair loss despite using finasteride, PRP treatments, and supplements like vitamin D, biotin, zinc, and iron. They are seeking advice on whether to continue with finasteride, increase the dosage, or try additional PRP sessions.
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
People are not using RU58841 for hair loss because it's not FDA approved, lacks long-term safety data, and is difficult to obtain and verify. They prefer FDA-approved treatments like minoxidil, finasteride, ketoconazole shampoo, and microneedling.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
A user shared a positive experience about receiving free finasteride from their dermatologist. Others discussed the varying costs of finasteride in different countries.
The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.
A user seeks a minoxidil and tretinoin foam-based product for improving a patchy beard in India. They are unsure about the safety of alcohol-based options for beard use.
The user is seeking cheaper options for finasteride and minoxidil in Canada, as their current treatment costs nearly $100 monthly. They mention insurance doesn't cover finasteride and face prescription limitations.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.
A 19-year-old has been using finasteride and oral minoxidil without desired results for hair loss and is seeking where to get dutasteride prescribed online. Various online sources for hair loss treatments, including dutasteride and RU58841, were suggested.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.